Efficacy and Safety of Mirabegron in Intracerebral Hemorrhage
Status:
Not yet recruiting
Trial end date:
2024-11-10
Target enrollment:
Participant gender:
Summary
Intracerebral hemorrhage (ICH) accounts for 10-15% of all strokes and is a common cause of
morbidity and mortality. Treatment options for ICH are limited, and with the exception of
craniotomy as a life-saving measure in critically cases, no pharmacological intervention has
shown significant efficacy in improving functional outcome after ICH. Inflammation after
intracerebral hemorrhage lead to edema around the hematoma after ICH, destruction of the
blood-brain barrier, and deterioration of neurological function. β3 adrenergic receptor
agonists promote the production of more immunomodulatory monocytes in bone marrow, thereby
reducing neuroinflammation and improving the prognosis of cerebral hemorrhage. Moreover, β3
adrenergic receptor agonists play an important role in regulating metabolism and
cardiovascular physiology and pathology. It is necessary to evaluate the safety and efficacy
of mirabegron in intracerebral hemorrhage, and explore new treatment methods for
intracerebral hemorrhage to meet clinical needs.